We have located links that may give you full text access.
Comparison of Fimasartan and Amlodipine Therapy on Carotid Atherosclerotic Plaque Inflammation.
Clinical Cardiology 2018 December 10
BACKGROUND: The renin-angiotensin system plays an important role in promoting atherosclerotic plaque inflammation, which may be inhibited by angiotension-II receptor blockers.
HYPOTHESIS: We investigated the effects of fimasartan and amlodipine therapy on carotid atherosclerotic plaque inflammation using 18 F-fluorodeoxyglucose (18 FDG) positron emission tomography (PET) imaging.
METHODS: Fifty patients with acute coronary syndrome and at least one lesion with 18 FDG uptake in the carotid artery (target to background ratio (TBR) ≥ 1.6) were randomly assigned to receive either fimasartan (60mg once a day) or amlodipine (5mg once a day). 18 FDG PET examinations were performed in all patients at baseline and 6 months. The primary endpoint was the percent change in the index vessel TBR for the most diseased segment (MDS TBR).
RESULTS: The two groups had similar baseline characteristics. At the 6 month follow-up, index vessel and aorta MDS TBR significantly decreased in both groups. However, the percent change in index vessel MDS TBR was similar between the two groups (-9.33±14.2% vs. -7.73±19.1%, respectively, p = 0.9). No significant difference was found for the percent change in the whole vessel TBR for the index vessel between the two groups, with similar findings for changes in MDS TBR or whole vessel TBR for the aorta. Total cholesterol, LDL cholesterol levels, and blood pressure improved to a similar degree in both groups.
CONCLUSIONS: Fimasartan and amlodipine reduce carotid atherosclerotic plaque inflammation similarly in patients with acute coronary syndrome, offering the same level of effectiveness.
HYPOTHESIS: We investigated the effects of fimasartan and amlodipine therapy on carotid atherosclerotic plaque inflammation using 18 F-fluorodeoxyglucose (18 FDG) positron emission tomography (PET) imaging.
METHODS: Fifty patients with acute coronary syndrome and at least one lesion with 18 FDG uptake in the carotid artery (target to background ratio (TBR) ≥ 1.6) were randomly assigned to receive either fimasartan (60mg once a day) or amlodipine (5mg once a day). 18 FDG PET examinations were performed in all patients at baseline and 6 months. The primary endpoint was the percent change in the index vessel TBR for the most diseased segment (MDS TBR).
RESULTS: The two groups had similar baseline characteristics. At the 6 month follow-up, index vessel and aorta MDS TBR significantly decreased in both groups. However, the percent change in index vessel MDS TBR was similar between the two groups (-9.33±14.2% vs. -7.73±19.1%, respectively, p = 0.9). No significant difference was found for the percent change in the whole vessel TBR for the index vessel between the two groups, with similar findings for changes in MDS TBR or whole vessel TBR for the aorta. Total cholesterol, LDL cholesterol levels, and blood pressure improved to a similar degree in both groups.
CONCLUSIONS: Fimasartan and amlodipine reduce carotid atherosclerotic plaque inflammation similarly in patients with acute coronary syndrome, offering the same level of effectiveness.
Full text links
Trending Papers
A Personalized Approach to the Management of Congestion in Acute Heart Failure.Heart International 2023
Potential Mechanisms of the Protective Effects of the Cardiometabolic Drugs Type-2 Sodium-Glucose Transporter Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Heart Failure.International Journal of Molecular Sciences 2024 Februrary 21
The Effect of Albumin Administration in Critically Ill Patients: A Retrospective Single-Center Analysis.Critical Care Medicine 2024 Februrary 8
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app